Wyatt McDonnell
CEO/Co-Founder
Infinimmune
Infinimmune uses its Complete Human sequencing technology® to capture fully paired heavy‑light antibody sequences from up to 300 million B cells, building the world’s largest database of natural human antibodies. Its Anthrobody® library‑on‑B‑cell platform and GLIMPSE™ AI‑driven language model enable rapid selection, affinity maturation, and developability optimization, delivering fully human therapeutic candidates in as little as eight weeks for biopharma and research partners.
- Artificial Intelligence
- Biotechnology
Updated 15 days ago
Funding
Raised to date
$12MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Therapeutic antibody discovery relies on artificial libraries and limited screening throughput, leading to long development timelines and a high risk of missing rare, high‑affinity human antibodies that have already been vetted by natural immune responses.
Solution
Infinimmune leverages the natural diversity of human B‑cell repertoires to identify and engineer therapeutic antibodies. Their Complete Human sequencing technology® captures fully paired heavy‑light chain sequences from up to 300 million B cells across hundreds of targets, creating an Anthrobody® library‑on‑B‑cell platform. Using native specificity, cross‑reactivity, and affinity data, they select optimal candidates and further refine them with the GLIMPSE™ antibody language model, which combines in‑silico prediction and wet‑lab validation to improve affinity, potency, and developability. This integrated pipeline can progress from discovery to lead generation in as little as 8 weeks, delivering fully human antibodies that have already been stress‑tested by evolution.
Target Audience
Primary customers are biopharma companies and research organizations seeking fast, high‑quality human antibody candidates for therapeutic development, particularly in immunology and inflammatory disease areas.
Features
- Massive paired heavy‑light chain sequencing of up to 300 M B cells, providing a world‑scale database of millions of natural antibody sequences
- Anthrobody® library‑on‑B‑cell platform that preserves native antigen specificity and cross‑reactivity of ultra‑rare clones
- GLIMPSE™ AI‑driven antibody language model for rapid in‑silico affinity maturation and developability assessment
- End‑to‑end workflow from discovery to lead optimization in approximately 8 weeks
- Validation pipeline covering specificity, functionality, and target mapping for hundreds of disease‑relevant antigens